PRMT1 (Protein Arginine Methyltransferase 1) is a key enzyme in the protein arginine methylation process, catalyzing the transfer of methyl groups to arginine residues on histone and non-histone substrates. As a member of the PRMT family, PRMT1 primarily mediates asymmetric dimethylation (ADMA) of arginine, a post-translational modification involved in epigenetic regulation, transcriptional activation, and signal transduction. It plays critical roles in DNA repair, RNA processing, and cellular differentiation by modifying histones (e.g., H4R3me2a) and non-histonic proteins like p53. EGFR, and RNA-binding proteins. Dysregulation of PRMT1 has been linked to cancers (e.g., leukemia, breast cancer), cardiovascular diseases, and metabolic disorders, making it a therapeutic target of interest.
PRMT1 antibodies are essential tools for studying its expression, localization, and function. These antibodies are widely used in techniques such as Western blotting, immunoprecipitation, chromatin immunoprecipitation (ChIP), and immunofluorescence. High-quality PRMT1 antibodies specifically recognize distinct isoforms (e.g., PRMT1_v1/v2) or methylation states, aiding in research on isoform-specific activities. Validation methods, including knockout cell lines or siRNA knockdown, are crucial to confirm antibody specificity. Commercial PRMT1 antibodies are typically raised in rabbits or mice, with applications in both basic research and clinical studies to explore PRMT1's role in disease mechanisms or drug development. Reliable antibodies enable precise detection of PRMT1 dynamics across tissues, cell types, and disease states.